Conduct interim analysis of the phase 3 INNOVATE-3 trial in recurrent ovarian cancer
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 30 Sep 2021
- Delivered
- March 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Interim analysis of phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer (Q3 2021)”
What we found
Evidence strength A What the grades mean
The 10-K filed February 2022 said the interim analysis would occur in 2022. Later filings report a DMC interim analysis of INNOVATE-3 announced in March 2022, after the Q3 2021 deadline.
-
A NovoCure Ltd 10-K filed 2022-02-24
“A DMC will conduct the pre-specified interim analysis pursuant to the study protocol in 2022 and data is anticipated in 2023.” ✓ confirmed on the page
-
A NovoCure Ltd 10-Q filed 2022-04-28
“In March 2022, we announced that an independent data monitoring committee ("DMC") conducted a pre-specified interim analysis for the phase 3 pivotal INNOVATE-3 study for the treatment of platinum-resistant ovarian cancer.” ✓ confirmed on the page
-
A NovoCure Ltd 10-Q filed 2022-07-28
“The interim analysis did not indicate a need to increase the patient sample size and the DMC recommended that the study should continue to final analysis as planned.” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Conduct
- Deliverable
- INNOVATE-3 phase 3 interim analysis
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you NovoCure Ltd? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-NVCR-024686 · Corrections policy